Intravenous gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age. It may help visualize and detect vascular abnormalities in the blood brain barrier (BBB) and central nervous system (CNS).
In patients with impaired renal function, gadolinium based contrast agents increase the risk of nephrogenic systemic fibrosis (NSF). A physician should be contacted if symptoms of NSF are encountered, such as dark or red patches on the skin; stiffness in joints; trouble moving, bending or straightening arms, hands, legs or feet; burning, itching, swelling, scaling, hardening and tightening of skin; pain in hip bones or ribs; or muscle weakness.
Common adverse reactions that may be experienced include headache, nausea, feeling hot, abnormal taste, and warmth, burning or pain local to the injection site.
General precautions should be taken in patients who are pregnant or breastfeeding, or who have a history of allergic reaction to contrast media, bronchial asthma or an allergic respiratory disorder.
Gadobutrol is indicated for use with magnetic resonance imaging for the following diagnostic processes:
Brigham and Women's Hospital, Boston, Massachusetts, United States
University of Connecticut Health Center, Farmington, Connecticut, United States
People's Hospital, Peking University, Peking, Beijing, China
Central Illinois Radiological Associates; OSF St. Francis Hospital Peoria, Peoria, Illinois, United States
UMass Chan Medical School, Worcester, Massachusetts, United States
The Pennsylvania State University, State College, Pennsylvania, United States
Fakultni nemocnice Plzen - Lochotin, Plzen, Czechia
Sanatorio Allende | Departamento de Investigación Clínica, Córdoba, Argentina
Hôpital Bichat Claude Bernard - Service de radiologie, Paris, France
Fakultni nemocnice Plzen - Lochotin, Plzen, Czechia
Szent Damjan Gorogkatolikus Korhaz, Kisvarda, Hungary
Idegsebeszeti Klinika, Pecs, Hungary
UPMC Magee Women's Hospital, Pittsburgh, Pennsylvania, United States
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
Northwestern University- Feinberg School of Medicine, Chicago, Illinois, United States
Northwestern University, Chicago, Illinois, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.